绥美凯是阻断药吗

Suimeike (dolute abalamide tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir. Today let’s take a closer look at whether Suimeikan is a blocking drug?

Suimeikai is an imported drug that is specially used for blocking. Suimeike (dolutegravir tablets) is the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of high efficacy, good tolerance, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-tablet compound preparation Trimeq (dolute abalamib tablets) with the new generation integrase inhibitor dolutegravir (DTG) as the core for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Trimicay (dolutegravir) is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer. The drug is based on the treatment plan of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014.

Suimeike (dolute abalamib tablets) has strong competitiveness in the market: on the one hand, it combines several anti-HIV drugs with different mechanisms to achieve a combined treatment effect; on the other hand, it is convenient to take, which greatly increases the patient's compliance with taking the drug, makes it easier to be accepted by the patient, and reduces the impact of the patient's inability to take the drug on time and in the dose.

The usage and dosage of Suimeikai (Dotiabalamid Tablets) is to be taken under the guidance of a physician with experience in HIV infection. Dosage: Adults and Adolescents (Weight of at least 40kg) For adults and adolescents, the recommended dose of Sumeika is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax as this product is a fixed-dose tablet and the dose cannot be reduced (see inner package insert for details). We need to be cautious about the usage and dosage of Suimeikai. In addition to strictly following the doctor's instructions, we also need to use it strictly in accordance with the instructions.

The above is the drug introduction of Suimeikai (Domitabalamid Tablets), I hope it can help you!